A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Sunday 6 October 2013

RPC reports four SPC decisions

In case you missed it, the recently-published August 2013 issue of the Reports of Patent, Design and Trade Mark Cases (RPC), produced on behalf of the UK's Intellectual Property Office by Oxford University Press, was entirely dedicated to reports of cases involving SPCs.  The cases are:

* Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents (Court of Justice of the European Union)

* Actavis Group PTC EHF v Sanofi (Patents Court, England and Wales)

* AstraZeneca AB v Comptroller-General of Patents (Patents Court, England and Wales)

* GlaxoSmithKline Biologicals SA v Comptroller-General of Patents (Patents Court, England and Wales).

The RPC is an official law report, published since 1884 and suitable for citation in UK litigation.

No comments: